Model-based impact and cost-effectiveness of cervical cancer prevention in the extended middle east and North Africa (EMENA)

Vaccine

Volumn 31, Issue S6, 2013, Pages

  Kim, Jane J ^a   Sharma, Monisha ^a   O'Shea, Meredith ^a   Sweet, Steven ^a   Diaz, Mireia ^b   Sancho Garnier, Hélène ^c   Seoud, Muhieddine ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIV MONTPELLIER   (France)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Cost effectiveness; Extended Middle East; HPV; Mathematical model; North Africa

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ALGERIA; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CHILD; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; LEBANON; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MIDDLE EAST; MULTICENTER STUDY; NORTH AFRICA; POPULATION SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; TURKEY (REPUBLIC); UNCERTAINTY; UTERINE CERVIX CANCER;

COST-EFFECTIVENESS; EXTENDED MIDDLE EAST; HPV; MATHEMATICAL MODEL; NORTH AFRICA;

ADOLESCENT; ADULT; AFRICA, NORTHERN; AGED; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MIDDLE EAST; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84890018232     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.096     Document Type: Review

References (53)

1. Vaccarella S., Bruni L., Seoud M. Burden of human papillomavirus infections and related diseases in the Extended Middle East and North Africa region. Vaccine 2013, 31S:G32-G44.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
3. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
4. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Africa. Summary Report 2010. Available at: (last accessed June 2013). http://www.hpvcentre.net/.
5. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Asia. Summary Report 2010. Available at: www.hpvcentre.net/ (last accessed June 2013).
6. Mroueh A.M., Seoud M.A., Kaspar H.G., Zalloua P.A. Prevalence of genital human papillomavirus among Lebanese women. Eur J Gynaecol Oncol 2002, 23(5):429-432.
7. Khodakarami N., Clifford G.M., Yavari P., Farzaneh F., Salehpour S., Broutet N., et al. Human papillomavirus infection in women with and without cervical cancer in Tehran. Iran. Int J Cancer 2011.
8. Ertem G. Awareness of cervical cancer risk factors and screening behaviour among nurses in a rural region of Turkey. Asian Pac J Cancer Prev 2009, 10(5):735-738.
9. Sancho-Garnier H., Chami Khazraji Y., Hamdi Cherif M., Mahnane A., Hsairi M., El Shalakamy A., et al. Overview of cervical cancer screening practices in the Extended Middle East and North Africa countries. Vaccine 2013, 31S:G51-G57.
10. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360(14):1385-1394.
11. Zhao F.H., Lin M.J., Chen F., Hu S.Y., Zhang R., Belinson J.L., et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010, 11(12):1160-1171.
12. Koliopoulos G., Arbyn M., Martin-Hirsch P., Kyrgiou M., Prendiville W., Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007, 104(1):232-246.
13. Abdel Aziz MT, Abdel Aziz MZ, Atta HM, Shaker OG, Abdel Fattah MM, Mohsen GA, et al. Screening for human papillomavirus (HPV) in Egyptian women by the second-generation hybrid capture (HC II) test. Med Sci Monit 2006 Jul;12(7):MT43-9.
14. Dursun P., Altuntas B., Kuscu E., Ayhan A. Women's knowledge about human papillomavirus and their acceptance of HPV vaccine. Aust N Z J Obstet Gynaecol 2009, 49(2):202-206.
15. Baykal C., Al A., Ugur M.G., Cetinkaya N., Attar R., Arioglu P. Knowledge and interest of Turkish women about cervical cancer and HPV vaccine. Eur J Gynaecol Oncol 2008, 29(1):76-79.
16. Durusoy R., Yamazhan M., Tasbakan M.I., Ergin I., Aysin M., Pullukcu H., et al. HPV vaccine awareness and willingness of first-year students entering university in Western Turkey. Asian Pac J Cancer Prev 2010, 11(6):1695-1701.
17. Al-Nuaimi NS, Al-Ghas YS, Al-Owais AH, Grivna M, Schneider J, Nagelkerke NJ, et al. Human papillomavirus vaccination uptake and factors related to uptake in a traditional desert city in the United Arab Emirates. Int J STD AIDS Jul;22(7):400-4.
18. Disease Control Priorities Project (DCPP). Available at: http://www.dcp2.org/main/Home.html (last accessed June 2013).
19. Drummond M.F., Drummond M.F.Mfteeohcp Methods for the economic evaluation of health care programmes. 3rd ed 2005, Oxford New York, Oxford University Press.
20. World Health Organization (WHO). Statistical Information System: CHOICE (CHOosing Interventions that are Cost Effective). Available at: http://www.who.int/choice/en/(last accessed June 2013).
21. World Health Organization (WHO). Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva:World Health Organization, 2001.
22. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008 Aug 19;26 Suppl 11:L59-72.
23. Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008 Aug 19;26 Suppl 12:M17-29.
24. Goldie S.J., O'Shea M., Campos N.G., Diaz M., Sweet S., Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26(32):4080-4093.
25. United Nations (UN), Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2008 Revision. CD-ROM Edition - Extended Dataset (United Nations publications, Sales No. E.05.XIII.12). 2009.
26. Murray CJL, Lopez AD, Harvard School of Public Health., World Health Organization., World Bank. Estimating causes of death: new methods and global and regional applications for 1990. In The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank; Distributed by Harvard University Press, 1996.
27. GAVI Alliance Countries eligible for support. Available at: (last accessed June 2013). http://www.gavialliance.org/support/apply/countries-eligible-for-support/.
28. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2011, 11(11):1048-1056.
29. World Health Organization (WHO). Life tables for WHO member states: 2009. Available from: (last accessed June 2013). http://www.who.int/gho/mortality_burden_disease/life_tables/en/.
30. Diaz M., Kim J.J., Albero G., de Sanjose S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008, 99(2):230-238.
31. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25(33):6257-6270.
32. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007, 166(2):137-150.
33. Diaz M., de Sanjose S., Ortendahl J., O'Shea M., Goldie S.J., Bosch F.X., et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010, 46(16):2973-2985.
34. Campos N.G., Kim J.J., Castle P.E., Ortendahl J.D., O'Shea M., Diaz M., et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2011, 130(11):2672-2684.
35. Sharma M., Ortendahl J., van der Ham E., Sy S., Kim J.J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG 2011, 119(2):166-176.
36. Kim J.J., Kobus K.E., Diaz M., O'Shea M., Van Minh H., Goldie S.J. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008, 26(32):4015-4024.
37. Esin M.N., Bulduk S., Ardic A. Beliefs about cervical cancer screening among Turkish married women. J Cancer Educ 2011 Sep, 26(3):510-515.
38. Acharya A., Diaz-Ortega J.L., Tambini G., de Quadros C., Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine 2002 Sep 10, 20(27-28):3332-3341.
39. Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system Geneva: World Health Organization 2002, Department of Vaccines and Biologicals.
40. Walker D., Mosqueira N.R., Penny M.E., Lanata C.F., Clark A.D., Sanderson C.F., et al. Variation in the costs of delivering routine immunization services in Peru. Bull World Health Organ 2004 Sep, 82(9):676-682.
41. Wolfson L.J., Gasse F., Lee-Martin S.P., Lydon P., Magan A., Tibouti A., et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 2008, 86(1):27-39.
42. Mennini F.S., Giorgi Rossi P., Palazzo F., Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009, 112(2):370-376.
43. La Torre G., de Waure C., Chiaradia G., Mannocci A., Capri S., Ricciardi W. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine 2010, 28(19):3379-3384.
44. Goldhaber-Fiebert J.D., Goldie S.J. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 2006, 4:13.
45. World Health Organization (WHO). Alphabetical list of WHO member states. Available at: (last accessed June 2013). http://www.who.int/choice/demography/by_country/en/index.html.
46. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
47. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2011, 13(1):78-88.
48. Mohtasham G., Shamsaddin N., Bazargan M., Anosheravan K., Elaheh M., Fazlolah G. Correlates of the intention to remain sexually inactive among male adolescents in an Islamic country: case of the Republic of Iran. J Sch Health 2009, 79(3):123-129.
49. Farahani F.K., Cleland J., Mehryar A.H. Associations between family factors and premarital heterosexual relationships among female college students in Tehran. Int Perspect Sex Reprod Health 2011, 37(1):30-39.
50. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008 Mar 14;26 Suppl 1:A16-23.
51. Belinson S.E., Belinson J.L. Human papillomavirus DNA testing for cervical cancer screening: practical aspects in developing countries. Mol Diagn Ther 2010, 14(4):215-222.
52. Gravitt P.E., Belinson J.L., Salmeron J., Shah K.V. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer 2011, 129(3):517-527.
53. World Bank World Development Indicators. Available at: (last accessed June 2013). http://data.worldbank.org/data-catalog/world-development-indicators.